vs
Side-by-side financial comparison of ICU MEDICAL INC (ICUI) and PORTLAND GENERAL ELECTRIC CO (POR). Click either name above to swap in a different company.
PORTLAND GENERAL ELECTRIC CO is the larger business by last-quarter revenue ($889.0M vs $540.7M, roughly 1.6× ICU MEDICAL INC). PORTLAND GENERAL ELECTRIC CO runs the higher net margin — 4.6% vs -2.9%, a 7.5% gap on every dollar of revenue. On growth, PORTLAND GENERAL ELECTRIC CO posted the faster year-over-year revenue change (7.9% vs -14.1%). ICU MEDICAL INC produced more free cash flow last quarter ($36.0M vs $-142.0M). Over the past eight quarters, PORTLAND GENERAL ELECTRIC CO's revenue compounded faster (-2.2% CAGR vs -2.3%).
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
Portland General Electric (PGE) is a Fortune 1000, publicly traded energy company based in Portland, Oregon, that generates, transmits and distributes electricity, serving almost two-thirds of Oregon's commercial and industrial activity. PGE is regulated by the Oregon Public Utility Commission. Founded in 1888 as the Willamette Falls Electric Company, the company has been an independent company for most of its existence, though was briefly owned by the Houston-based Enron Corporation from 199...
ICUI vs POR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $540.7M | $889.0M |
| Net Profit | $-15.7M | $41.0M |
| Gross Margin | 37.5% | — |
| Operating Margin | 1.0% | 10.7% |
| Net Margin | -2.9% | 4.6% |
| Revenue YoY | -14.1% | 7.9% |
| Net Profit YoY | 34.0% | 7.9% |
| EPS (diluted) | $-0.63 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $540.7M | $889.0M | ||
| Q3 25 | $537.0M | $952.0M | ||
| Q2 25 | $548.9M | $807.0M | ||
| Q1 25 | $604.7M | $928.0M | ||
| Q4 24 | $629.8M | $824.0M | ||
| Q3 24 | $589.1M | $929.0M | ||
| Q2 24 | $596.5M | $758.0M | ||
| Q1 24 | $566.7M | $929.0M |
| Q4 25 | $-15.7M | $41.0M | ||
| Q3 25 | $-3.4M | $103.0M | ||
| Q2 25 | $35.3M | $62.0M | ||
| Q1 25 | $-15.5M | $100.0M | ||
| Q4 24 | $-23.8M | $38.0M | ||
| Q3 24 | $-33.0M | $94.0M | ||
| Q2 24 | $-21.4M | $72.0M | ||
| Q1 24 | $-39.5M | $109.0M |
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 32.7% | — |
| Q4 25 | 1.0% | 10.7% | ||
| Q3 25 | 2.6% | 18.3% | ||
| Q2 25 | 1.9% | 14.6% | ||
| Q1 25 | 2.1% | 18.1% | ||
| Q4 24 | 6.0% | 10.7% | ||
| Q3 24 | 1.4% | 15.7% | ||
| Q2 24 | 1.3% | 15.3% | ||
| Q1 24 | -1.9% | 17.4% |
| Q4 25 | -2.9% | 4.6% | ||
| Q3 25 | -0.6% | 10.8% | ||
| Q2 25 | 6.4% | 7.7% | ||
| Q1 25 | -2.6% | 10.8% | ||
| Q4 24 | -3.8% | 4.6% | ||
| Q3 24 | -5.6% | 10.1% | ||
| Q2 24 | -3.6% | 9.5% | ||
| Q1 24 | -7.0% | 11.7% |
| Q4 25 | $-0.63 | $0.36 | ||
| Q3 25 | $-0.14 | $0.94 | ||
| Q2 25 | $1.43 | $0.56 | ||
| Q1 25 | $-0.63 | $0.91 | ||
| Q4 24 | $-0.97 | $0.34 | ||
| Q3 24 | $-1.35 | $0.90 | ||
| Q2 24 | $-0.88 | $0.69 | ||
| Q1 24 | $-1.63 | $1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $4.7B |
| Stockholders' EquityBook value | $2.1B | $4.1B |
| Total Assets | $4.1B | $13.2B |
| Debt / EquityLower = less leverage | — | 1.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | — | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | — | ||
| Q1 24 | $251.4M | — |
| Q4 25 | — | $4.7B | ||
| Q3 25 | — | $4.7B | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | — | $4.4B |
| Q4 25 | $2.1B | $4.1B | ||
| Q3 25 | $2.1B | $4.0B | ||
| Q2 25 | $2.1B | $3.9B | ||
| Q1 25 | $2.0B | $3.8B | ||
| Q4 24 | $2.0B | $3.8B | ||
| Q3 24 | $2.0B | $3.6B | ||
| Q2 24 | $2.0B | $3.5B | ||
| Q1 24 | $2.1B | $3.5B |
| Q4 25 | $4.1B | $13.2B | ||
| Q3 25 | $4.1B | $13.0B | ||
| Q2 25 | $4.1B | $12.7B | ||
| Q1 25 | $4.2B | $12.7B | ||
| Q4 24 | $4.2B | $12.5B | ||
| Q3 24 | $4.3B | $11.9B | ||
| Q2 24 | $4.3B | $11.6B | ||
| Q1 24 | $4.3B | $11.6B |
| Q4 25 | — | 1.13× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 1.23× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.20× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 1.27× | ||
| Q1 24 | — | 1.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.6M | $148.0M |
| Free Cash FlowOCF − Capex | $36.0M | $-142.0M |
| FCF MarginFCF / Revenue | 6.6% | -16.0% |
| Capex IntensityCapex / Revenue | 4.6% | 32.6% |
| Cash ConversionOCF / Net Profit | — | 3.61× |
| TTM Free Cash FlowTrailing 4 quarters | $91.8M | $-71.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.6M | $148.0M | ||
| Q3 25 | $56.7M | $403.0M | ||
| Q2 25 | $11.2M | $336.0M | ||
| Q1 25 | $51.3M | $231.0M | ||
| Q4 24 | $40.2M | $170.0M | ||
| Q3 24 | $36.1M | $244.0M | ||
| Q2 24 | $82.0M | $189.0M | ||
| Q1 24 | $45.8M | $175.0M |
| Q4 25 | $36.0M | $-142.0M | ||
| Q3 25 | $27.6M | $100.0M | ||
| Q2 25 | $-8.5M | $99.0M | ||
| Q1 25 | $36.7M | $-128.0M | ||
| Q4 24 | $16.1M | $-222.0M | ||
| Q3 24 | $16.2M | $-9.0M | ||
| Q2 24 | $62.5M | $-109.0M | ||
| Q1 24 | $29.9M | $-150.0M |
| Q4 25 | 6.6% | -16.0% | ||
| Q3 25 | 5.1% | 10.5% | ||
| Q2 25 | -1.5% | 12.3% | ||
| Q1 25 | 6.1% | -13.8% | ||
| Q4 24 | 2.6% | -26.9% | ||
| Q3 24 | 2.7% | -1.0% | ||
| Q2 24 | 10.5% | -14.4% | ||
| Q1 24 | 5.3% | -16.1% |
| Q4 25 | 4.6% | 32.6% | ||
| Q3 25 | 5.4% | 31.8% | ||
| Q2 25 | 3.6% | 29.4% | ||
| Q1 25 | 2.4% | 38.7% | ||
| Q4 24 | 3.8% | 47.6% | ||
| Q3 24 | 3.4% | 27.2% | ||
| Q2 24 | 3.3% | 39.3% | ||
| Q1 24 | 2.8% | 35.0% |
| Q4 25 | — | 3.61× | ||
| Q3 25 | — | 3.91× | ||
| Q2 25 | 0.32× | 5.42× | ||
| Q1 25 | — | 2.31× | ||
| Q4 24 | — | 4.47× | ||
| Q3 24 | — | 2.60× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 1.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
POR
| Other | $507.0M | 57% |
| Commercial | $231.0M | 26% |
| Industrial | $140.0M | 16% |
| Direct Accesscustomers | $11.0M | 1% |
